NO20053304L - NOGO A bindingsmolekyler og farmasoytisk anvendelse av disse - Google Patents

NOGO A bindingsmolekyler og farmasoytisk anvendelse av disse

Info

Publication number
NO20053304L
NO20053304L NO20053304A NO20053304A NO20053304L NO 20053304 L NO20053304 L NO 20053304L NO 20053304 A NO20053304 A NO 20053304A NO 20053304 A NO20053304 A NO 20053304A NO 20053304 L NO20053304 L NO 20053304L
Authority
NO
Norway
Prior art keywords
human
nogo
binding molecule
binding molecules
pharmaceutical use
Prior art date
Application number
NO20053304A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053304D0 (no
Inventor
Martin E Schwab
Carmen Barske
Anis Khusro Mir
Thomas Oertle
Lisa Schnell
Alessandra Vitaliti
Mauro Zurini
Original Assignee
Univ Zuerich Prorektorat Forsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich Prorektorat Forsc filed Critical Univ Zuerich Prorektorat Forsc
Publication of NO20053304D0 publication Critical patent/NO20053304D0/no
Publication of NO20053304L publication Critical patent/NO20053304L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20053304A 2002-12-10 2005-07-06 NOGO A bindingsmolekyler og farmasoytisk anvendelse av disse NO20053304L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0228832.2A GB0228832D0 (en) 2002-12-10 2002-12-10 Organic compound
PCT/EP2003/013960 WO2004052932A2 (en) 2002-12-10 2003-12-09 Antibody (“11c7”) anti nogo a and its pharmaceutical use

Publications (2)

Publication Number Publication Date
NO20053304D0 NO20053304D0 (no) 2005-07-06
NO20053304L true NO20053304L (no) 2005-09-07

Family

ID=9949456

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053304A NO20053304L (no) 2002-12-10 2005-07-06 NOGO A bindingsmolekyler og farmasoytisk anvendelse av disse

Country Status (25)

Country Link
US (2) US7785593B2 (es)
EP (1) EP1572745B1 (es)
JP (1) JP4504200B2 (es)
KR (1) KR101215801B1 (es)
CN (1) CN100384877C (es)
AT (1) ATE475671T1 (es)
AU (1) AU2003289998B2 (es)
BR (1) BR0317161A (es)
CA (1) CA2509068C (es)
CY (1) CY1110848T1 (es)
DE (1) DE60333585D1 (es)
DK (1) DK1572745T3 (es)
EC (1) ECSP055849A (es)
ES (1) ES2349293T3 (es)
GB (1) GB0228832D0 (es)
HK (1) HK1084676A1 (es)
IL (1) IL169018A (es)
MX (1) MXPA05006265A (es)
NO (1) NO20053304L (es)
PL (1) PL210720B1 (es)
PT (1) PT1572745E (es)
RU (1) RU2350623C2 (es)
SI (1) SI1572745T1 (es)
WO (1) WO2004052932A2 (es)
ZA (1) ZA200504522B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
BRPI0417959A (pt) * 2003-12-22 2007-03-27 Glaxo Group Ltd anticorpo ou fragmento funcional deste, composição farmcêutica, método para tratamento ou profilaxia de acidente vascular cerebral e outras doenças/distúrbios neurológicos em um ser humano, uso de um anticorpo anti-nogo, e, métodos para inibir a neurodegeneração e/ou promover a recuperação funcional em um paciente humano, para promover o crescimento axonal, para produzir um anticorpo anti-nogo e para produzir uma composição farmacêutica intravenosamente administrável
NZ564567A (en) * 2005-07-05 2010-09-30 Glaxo Group Ltd Humanised antibodies specific for neurite outgrowth inhibitor-A and pharmaceutical uses thereof
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
ES2425768T3 (es) * 2007-11-02 2013-10-17 Novartis Ag Moléculas de unión a nogo-a mejoradas y uso farmacéutico de las mismas
WO2010004031A2 (en) * 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
WO2012004773A1 (en) 2010-07-09 2012-01-12 Universite De Geneve New uses of nogo-a inhibitors and related methods
CA2876284A1 (en) 2012-07-05 2014-01-09 Glaxo Group Limited Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
US20160135446A1 (en) * 2013-06-13 2016-05-19 Biomatrica, Inc. Cell stabilization
WO2017149538A1 (en) 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
KR20220087516A (ko) 2019-10-24 2022-06-24 노바고 테라퓨틱스 아게 신규 항-Nogo-A 항체

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5180820A (en) 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
ES2204890T3 (es) * 1991-03-06 2004-05-01 Merck Patent Gmbh Anticuerpos monoclonales humanizados.
DE69942803D1 (de) 1998-07-22 2010-11-11 Smithkline Beecham Ltd Rotein änhelt, und dafür kodierende cdns
CZ304224B6 (cs) 1998-11-06 2014-01-15 Schwab Monoklonální protilátka
CU22921A1 (es) 1999-11-16 2004-02-20 Centro Inmunologia Molecular Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
ATE466882T1 (de) * 2000-01-12 2010-05-15 Univ Yale Nogo rezeptor-vermittelte blockade des axonalen wachstums
US7318923B2 (en) 2001-04-30 2008-01-15 Eli Lilly And Company Humanized anti-βantibodies
DE20110806U1 (de) 2001-06-29 2001-12-20 Jack Wolfskin Ausruestung Fuer Zelt
ATE517855T1 (de) * 2001-11-30 2011-08-15 Biogen Idec Inc Antikörper gegen chemotaktische monozytenproteine
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
BRPI0417959A (pt) * 2003-12-22 2007-03-27 Glaxo Group Ltd anticorpo ou fragmento funcional deste, composição farmcêutica, método para tratamento ou profilaxia de acidente vascular cerebral e outras doenças/distúrbios neurológicos em um ser humano, uso de um anticorpo anti-nogo, e, métodos para inibir a neurodegeneração e/ou promover a recuperação funcional em um paciente humano, para promover o crescimento axonal, para produzir um anticorpo anti-nogo e para produzir uma composição farmacêutica intravenosamente administrável
US7596225B2 (en) * 2005-06-30 2009-09-29 Alcatl-Lucent Usa Inc. Method for refreshing a pairwise master key

Also Published As

Publication number Publication date
PL377506A1 (pl) 2006-02-06
DK1572745T3 (da) 2010-10-25
US20110059110A1 (en) 2011-03-10
KR20050095768A (ko) 2005-09-30
EP1572745A2 (en) 2005-09-14
CA2509068C (en) 2012-02-07
RU2005121669A (ru) 2007-01-20
DE60333585D1 (de) 2010-09-09
ES2349293T3 (es) 2010-12-29
US7785593B2 (en) 2010-08-31
CY1110848T1 (el) 2015-06-10
HK1084676A1 (en) 2006-08-04
CN1747971A (zh) 2006-03-15
US8535666B2 (en) 2013-09-17
CA2509068A1 (en) 2004-06-24
AU2003289998A1 (en) 2004-06-30
SI1572745T1 (sl) 2010-12-31
AU2003289998B2 (en) 2008-02-14
NO20053304D0 (no) 2005-07-06
PL210720B1 (pl) 2012-02-29
US20060183678A1 (en) 2006-08-17
ATE475671T1 (de) 2010-08-15
MXPA05006265A (es) 2005-12-05
JP2006523087A (ja) 2006-10-12
IL169018A (en) 2012-07-31
KR101215801B1 (ko) 2012-12-26
PT1572745E (pt) 2010-10-21
EP1572745B1 (en) 2010-07-28
ZA200504522B (en) 2006-03-29
ECSP055849A (es) 2005-09-20
RU2350623C2 (ru) 2009-03-27
CN100384877C (zh) 2008-04-30
GB0228832D0 (en) 2003-01-15
WO2004052932A2 (en) 2004-06-24
JP4504200B2 (ja) 2010-07-14
WO2004052932A3 (en) 2004-10-21
BR0317161A (pt) 2005-11-01

Similar Documents

Publication Publication Date Title
NO20053304L (no) NOGO A bindingsmolekyler og farmasoytisk anvendelse av disse
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
ECSP056263A (es) Anticuerpos humanizados que reconocen el péptido beta amiloideo
ATE416190T1 (de) Polypeptide mit bindungsaffinität für her2
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
EA200700136A1 (ru) Анти-cd154-антитела
WO2007039818A8 (en) Antigen binding molecules having modified fc regions and altered binding to fc receptors
TW200635946A (en) Binding proteins specific for human matriptase
WO2006083964A3 (en) Modified fusion molecules for treatment of allergic disease
WO2007039256A3 (de) Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
NO20061678L (no) NOGO-A bindingsmolekyler og funmsoytiske anvendelser derav
DE602004016499D1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
DE602006020333D1 (de) Multimere fc-rezeptor-polypeptide
PE20021098A1 (es) ANTICUERPOS ESPECIFICOS DE CD44v6
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
RS20050577A (en) Compositions and methods for treating cancer using igsf9 and liv-1
DE60228504D1 (de) P53 bindende t-zellrezeptormoleküle und deren verwendungen
PE20090981A1 (es) Moleculas aglutinantes de nogo-a mejoradas y uso farmaceutico de las mismas
MXPA02005236A (es) Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos.
WO2004032832A3 (en) Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment
Cozma Determination of Primary Structure and Affinity Characterization of Naturally Occurring β-Amyloid Autoantibodies
CY1115920T1 (el) Αντι-gm-csf αντισωματα και χρησεις αυτων

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application